July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Improvement of type 3 neovascularization on OCT-A after combination therapy with bevacizumab and photodynamic therapy
Author Affiliations & Notes
  • Lisette Marline Smid
    Rotterdam Ophthalmic Institute, Rotterdam, Netherlands
  • Koenraad Arndt Vermeer
    Rotterdam Ophthalmic Institute, Rotterdam, Netherlands
  • King Tong Wong
    Rotterdam Eye Hospital, Netherlands
  • Jose P. Martinez ciriano
    Rotterdam Eye Hospital, Netherlands
  • Mirjam E.J. Van Velthoven
    Rotterdam Eye Hospital, Netherlands
  • Footnotes
    Commercial Relationships   Lisette Smid, Heidelberg Engineering (F); Koenraad Vermeer, Heidelberg Engineering (F); King Wong, None; Jose Martinez ciriano, None; Mirjam Van Velthoven, Allergan (R), Novartis (R)
  • Footnotes
    Support  Stichting Life Sciences Health TKI (LSHM16001), Heidelberg Engineering
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1150. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lisette Marline Smid, Koenraad Arndt Vermeer, King Tong Wong, Jose P. Martinez ciriano, Mirjam E.J. Van Velthoven; Improvement of type 3 neovascularization on OCT-A after combination therapy with bevacizumab and photodynamic therapy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1150.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The aim of this prospective observational cohort study was to explore the response of type 3 neovascularization due to AMD to combination therapy with intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) using optical coherence tomography angiography (OCT-A) imaging. Additionally, we compared two different sequences of the combination therapy.

Methods : Thirty eyes of 29 treatment-naïve patients with new-onset type 3 neovascularization based on conventional diagnostic imaging were included. They were treated with a combination of IVB and PDT 2 weeks apart. Treatment sequence for each patient, i.e. starting with IVB (IVB-first group) or starting with PDT (PDT-first group), was based on logistics. We performed OCT-A imaging (Spectralis OCTA, Heidelberg Engineering; Doppler OCT) at week 0 (baseline), 2, 4 and 18. Two independent medical retina specialists graded vascular and structural characteristics of the lesion over time based on OCT-A images as: increased, unchanged, decreased or resolved with respect to the baseline image. Primary parameters were intraretinal flow (IRF; vascular) and intraretinal cysts (IRC; structural). Best corrected visual acuity (BCVA in LogMAR) was measured at week 0 and 18. Non-parametric tests were used for statistical analysis (binominal, Wilcoxon Signed-Ranks and Mann-Whitney U tests).

Results : Seventeen eyes were in the IVB-first group (12 female, median age 83 years), and 13 in the PDT-first group (8 female, median age 82 years). Seven eyes were excluded for OCT-A analysis (4 from IVB-first group), and 1 eye for BCVA analysis (from IVB-first group). Analysis of all patients together revealed that most lesions were decreased or resolved after 2, 4 and 18 weeks based on the IRF and IRC scores (figure 1; p≤0.001). Median BCVA improved with 0.14 LogMAR after 18 weeks (p=0.04). Although not statistically significant, IRF and IRC were slightly more often resolved in the PDT-first group than in the IVB-first group (figure 2; p>0.05). Also, the median BCVA improved slightly more in the PDT-first group from baseline to week 18 (0.24 LogMAR) than in the IVB-first group (0.14 LogMAR; p=0.22).

Conclusions : Both the vascular, structural (OCT-A) and functional (BCVA) parameters improved after combination therapy with IVB and PDT in patients with type 3 neovascularization. Initial therapy with PDT tended to be most beneficial in our study.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.




This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.